Merck Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Merck verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 13.6%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 9.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 7.2%. Die Eigenkapitalrendite von Merck beträgt 19.5% und die Nettomargen betragen 13.6%.
Wichtige Informationen
13.57%
Wachstumsrate der Gewinne
13.75%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 5.95% |
| Wachstumsrate der Einnahmen | 7.23% |
| Eigenkapitalrendite | 19.45% |
| Netto-Marge | 13.59% |
| Nächste Ertragsaktualisierung | 04 Aug 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrativ-Update • May 21
Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026
Announcement Overview Analyst: Qudus Adebara (Founder, Wane Investment House) Merck & Co., Inc. (“Merck” or “the Company”), known as MSD outside the United States and Canada, has announced that it will present more than 100 abstracts spanning over 25 cancer types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , scheduled for May 29 – June 2, 2026.Narrativ-Update • May 19
Merck Completes Acquisition of Terns Pharmaceuticals
Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.
Narrativ-Update • May 17
MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance
Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.Seeking Alpha • May 16
A Futuristic Synthesis Indeed
Summary A recent paper by Merck details the industrial synthesis of enlicitide, which is a beast of a macrocyclic peptide. Just looking at the structure tells you that this must be a ferociously active molecule with huge commercial potential, because there is just no way that anyone is going to make this on scale - or find a way to make this on scale! - otherwise. Several companies have tried over the years to come up with a small-molecule approach that could lead to an orally dosed therapy as opposed to an injectable, and Merck has apparently made it over the finish line with this one. Read the full article on Seeking AlphaAnalyseartikel • May 11
Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...
Narrativ-Update • May 02
MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple
Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.Narrativ-Update • Apr 19
Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)
Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.Narrativ-Update • Apr 18
MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple
Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.
Narrativ-Update • Apr 04
MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside
Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.Narrativ-Update • Mar 21
MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple
The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.Narrativ-Update • Mar 06
MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside
Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.Narrativ-Update • Feb 20
MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance
Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.Narrativ-Update • Feb 06
MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple
Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.
Neues Narrativ • Jan 30
The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff
Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.Narrativ-Update • Jan 23
MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance
Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.Narrativ-Update • Jan 09
MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes
Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.Narrativ-Update • Dec 24
MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations
Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.Narrativ-Update • Dec 14
Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs
based on Q3 resultNarrativ-Update • Dec 10
MRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance
Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.Analyseartikel • Dec 02
Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85
Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...Narrativ-Update • Nov 26
MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead
Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.Analyseartikel • Nov 02
Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Merck & Co., Inc. ( NYSE:MRK ) came out with its quarterly results last week, and we wanted to see how the business is...Aufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Merck Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 65,768 | 8,935 | 10,277 | 15,651 |
| 31 Dec 25 | 65,011 | 18,254 | 10,115 | 15,614 |
| 30 Sep 25 | 64,235 | 19,034 | 10,073 | 12,746 |
| 30 Jun 25 | 63,616 | 16,406 | 10,135 | 15,163 |
| 31 Mar 25 | 63,922 | 17,434 | 10,186 | 14,668 |
| 31 Dec 24 | 64,168 | 17,117 | 10,100 | 14,481 |
| 30 Sep 24 | 63,174 | 12,148 | 10,050 | 22,200 |
| 30 Jun 24 | 62,480 | 13,736 | 9,847 | 18,868 |
| 31 Mar 24 | 61,403 | 2,306 | 9,839 | 18,592 |
| 31 Dec 23 | 60,115 | 365 | 9,884 | 18,342 |
| 30 Sep 23 | 59,315 | 4,608 | 9,839 | 12,556 |
| 30 Jun 23 | 58,311 | 3,111 | 9,934 | 12,881 |
| 31 Mar 23 | 57,869 | 13,030 | 9,851 | 12,433 |
| 31 Dec 22 | 59,283 | 14,519 | 9,669 | 11,918 |
| 30 Sep 22 | 58,974 | 15,322 | 9,840 | 11,923 |
| 30 Jun 22 | 57,169 | 16,641 | 9,776 | 10,940 |
| 31 Mar 22 | 53,978 | 13,910 | 9,489 | 10,515 |
| 31 Dec 21 | 48,704 | 12,345 | 9,403 | 11,942 |
| 30 Sep 21 | 46,131 | 5,908 | 9,260 | 10,725 |
| 30 Jun 21 | 43,906 | 3,665 | 8,845 | 10,678 |
| 31 Mar 21 | 41,857 | 4,793 | 8,669 | 10,339 |
| 31 Dec 20 | 41,518 | 4,519 | 8,569 | 10,564 |
| 30 Sep 20 | 42,438 | 9,492 | 8,812 | 9,079 |
| 30 Jun 20 | 43,906 | 9,070 | 9,200 | 8,818 |
| 31 Mar 20 | 46,312 | 9,399 | 9,700 | 8,990 |
| 31 Dec 19 | 39,121 | 5,690 | 8,829 | 8,594 |
| 30 Sep 19 | 45,970 | 9,314 | 9,604 | 8,489 |
| 30 Jun 19 | 44,367 | 9,362 | 9,586 | 7,997 |
| 31 Mar 19 | 43,073 | 8,399 | 9,467 | 8,084 |
| 31 Dec 18 | 42,294 | 6,220 | 9,587 | 9,254 |
| 30 Sep 18 | 41,729 | 3,347 | 9,541 | 9,251 |
| 30 Jun 18 | 41,259 | 1,341 | 9,554 | 11,680 |
| 31 Mar 18 | 40,725 | 1,579 | 9,449 | 11,182 |
| 31 Dec 17 | 40,122 | 2,394 | 9,560 | 9,845 |
| 30 Sep 17 | 39,804 | 2,845 | 9,615 | 9,427 |
| 30 Jun 17 | 40,016 | 5,086 | 9,612 | 6,916 |
| 31 Mar 17 | 39,929 | 4,346 | 9,713 | 7,035 |
| 31 Dec 16 | 39,807 | 3,920 | 9,313 | 6,921 |
| 30 Sep 16 | 39,907 | 5,492 | 9,193 | 6,849 |
| 30 Jun 16 | 39,444 | 5,133 | 9,312 | 6,828 |
| 31 Mar 16 | 39,385 | 4,614 | 9,776 | 6,518 |
| 31 Dec 15 | 39,498 | 4,442 | 9,799 | 6,613 |
| 30 Sep 15 | 39,765 | 10,781 | 10,262 | 6,727 |
| 30 Jun 15 | 40,249 | 9,850 | 10,756 | 6,644 |
Qualität der Erträge: MRK hat einen großen einmalig Verlust von $11.5B verbucht, der sich auf die Finanzergebnisse der letzten 12 Monate bis zum 31st March, 2026 auswirkt.
Wachsende Gewinnspanne: MRKDie aktuellen Gewinnspannen (13.6%) sind niedriger als im letzten Jahr (27.3%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: MRKIn den letzten 5 Jahren sind die Gewinne von 13.6% jährlich gestiegen.
Beschleunigtes Wachstum: MRKDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: MRK hatte im vergangenen Jahr ein negatives Gewinnwachstum (-48.7%), was einen Vergleich mit dem Branchendurchschnitt Pharmaceuticals (-5%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: MRKDie Eigenkapitalrendite des Unternehmens (19.5%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 10:44 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Merck & Co., Inc. wird von 48 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Emily Field | Barclays |